TBPH FY 2022 Earnings — Theravance Biopharma, Inc. Revenue & Financial Results | Market Cap Arena

TBPHTheravance Biopharma, Inc.

$716M

FY 2022 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$51M-7.2% YoY

Gross Profit

-$12M-23.5% margin

Operating Income

-$92M-179.1% margin

Net Income

$872M1698.5% margin

EPS (Diluted)

$-1.26

Cash Flow

Operating Cash Flow

-$187M

Free Cash Flow

-$188M

Stock-Based Comp.

$40M

Balance Sheet

Total Assets

$607M

Total Liabilities

$166M

Stockholders' Equity

$442M

Cash & Equivalents

$298M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$51M	$55M	-7.2%
Gross Profit	-$12M	-$138M	+91.3%
Operating Income	-$92M	-$258M	+64.3%
Net Income	$872M	-$199M	+537.3%